Verifying a blend is not the same exercise as verifying a single peptide. A lab receiving CJC-1295 (No-DAC) and Ipamorelin in one vial needs evidence that both components are present at the expected ratio and that neither is masking contamination in the other — which raises the analytical bar rather than simply doubling it.
Why a mixed vial complicates the chromatogram
High-performance liquid chromatography separates a sample by how its components interact with a stationary phase, and for a two-peptide blend this means the resulting trace should show two distinct, well-resolved peaks rather than one — with purity reported for each individually. An overlapping or poorly resolved peak pair is itself a warning sign, since it can hide a shortfall in one component behind an apparently acceptable combined reading. Background on how this analysis works in general is covered in understanding HPLC purity.
Confirming identity, not just quantity
Purity percentage alone doesn't confirm that the two peaks are actually CJC-1295 and Ipamorelin rather than two similarly-eluting impurities. Mass spectrometry addresses that gap by measuring the molecular mass of each separated component and comparing it against the expected mass for each peptide's known sequence. Running chromatography and mass spectrometry as complementary methods, rather than relying on either alone, is standard practice for any multi-component peptide product.
What a batch-specific COA should show for a blend
Because two peptides are involved, a proper Certificate of Analysis for this product should report purity, identity confirmation, and any relevant appearance or solubility notes for each component separately, tied to the specific production lot in the vial rather than to the product line generically. A single combined purity figure with no per-component breakdown is not sufficient documentation for a two-peptide blend. See how to read a certificate of analysis for what a complete report should include, and consider whether the supplier's COA has been corroborated by an independent, third-party lab rather than generated solely in-house.
What acceptable results look like
For a blend product, researchers generally expect each peptide to individually meet or exceed the same purity threshold quoted for the compound sold on its own — commonly in the range of 98% or higher by HPLC area. A batch that meets this bar for one peptide but falls noticeably short for the other is not equivalent to a blend that meets it for both, even if an average of the two would look acceptable on paper. This is one more reason per-component reporting, rather than a single blended number, is the meaningful standard to look for.
What testing can't tell you
Analytical purity testing confirms what a peptide is and how much of it is present relative to detectable impurities; it does not, by itself, confirm sterility, endotoxin levels, or that the two peptides were combined at the labeled mass ratio rather than skewed toward one component. Labs working with a two-peptide blend should treat purity data, ratio verification, and any sterility or endotoxin information as separate pieces of documentation rather than assuming one implies the others.
Product page: CJC-1295 (No-DAC) & Ipamorelin research blend.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.